ExpreS2ion CEO talking about partnering efforts at BIO-Europe
Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria vaccine. BioStock talked to CEO Bent U. Frandsen about this at the partnering conference BIO-Europe.
00:00 Opening
00:21 Introduction to ExpreS2ion Biotech
00:39 The company´s partnering efforts
01:18 Discussions with potential partners
01:51 Signed agreement with Serum Institute of India regarding malaria vaccine
02:38 Currently raising capital through warrant series TO10
03:38 Why ExpreS2ion Biotech is a compelling investment case
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
https://www.biostock.se/
#BioStock #LifeScience
About BioStock
BioStock is Scandinavia's leading digital news and analysis service, exclusively focusing on the Life Science sector. Our primary editorial office and TV studio are located at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies.